吸烟暴露人群伴或不伴COPD的支气管舒张反应性研究
该研究回顾性分析2,269名吸烟暴露的COPD研究参与者,评估持续、间歇或从未出现支气管舒张反应性(BDR)与哮喘病史、CT特征、血嗜酸性粒细胞及FEV1下降的关系。结果显示持续和间歇BDR均与哮喘病史及小气道病变相关,持续BDR与FEV1下降及GOLD 0期进展为COPD高风险相关。
要点
- 持续或间歇BDR与哮喘病史及小气道病变相关。
- 持续BDR与FEV1随时间下降相关。
- GOLD 0期持续BDR者进展为COPD风险更高。
核心结论
- 即使一次BDR阳性也提示存在哮喘病史和小气道病变的阻塞性肺疾病表型。
- 持续BDR与FEV1下降及GOLD 0期进展为COPD高风险相关。
研究设计与样本
- 回顾性分析2,269名吸烟暴露的COPD研究参与者,伴或不伴COPD。
- 使用多种BDR定义:FEV1变化≥200 mL且≥12%(FEV1-BDR)、FVC变化(FVC-BDR)、FEV1或FVC或两者变化(ATS-BDR)。
主要发现
- 持续和间歇ATS-BDR均与哮喘病史及更高的小气道病变(%PRM fSAD)相关,见于GOLD 0期和整个队列。
- FEV1-BDR和FVC-BDR定义下观察到类似结果。
- 嗜酸性粒细胞在各BDR组间无一致变化。
- 持续BDR与整个队列FEV1随时间下降相关。
- GOLD 0期中间歇ATS-BDR组(OR 3.20;95%CI 2.21-4.66;P<.001)和持续ATS-BDR组(OR 9.48;95%CI 3.77-29.12;P<.001)与进展为COPD相关。
关键数值与推荐
- BDR定义:FEV1变化≥200 mL且≥12%(FEV1-BDR)、FVC变化(FVC-BDR)、FEV1或FVC或两者变化(ATS-BDR)。
- GOLD 0期进展为COPD的OR:间歇ATS-BDR 3.20(95%CI 2.21-4.66;P<.001),持续ATS-BDR 9.48(95%CI 3.77-29.12;P<.001)。
临床怎么用
- 对吸烟暴露人群应关注BDR,即使单次阳性也提示哮喘病史和小气道病变表型。
- 持续BDR者需监测FEV1下降及COPD进展风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bronchodilator responsiveness (BDR) in obstructive lung disease varies over time and may be associated with distinct clinical features. RESEARCH QUESTION: Is consistent BDR over time (always present) differentially associated with obstructive lung disease features relative to inconsistent (sometimes present) or never (never present) BDR in tobacco-exposed people with or without COPD? STUDY DESIGN AND METHODS: We retrospectively analyzed data from 2,269 tobacco-exposed participants in the Subpopulations and Intermediate Outcome Measures in COPD Study with or without COPD. We used various BDR definitions: change of ≥ 200 mL and ≥ 12% in FEV1 (FEV1-BDR), change in FVC (FVC-BDR), and change in in FEV1, FVC or both (ATS-BDR). Using generalized linear models adjusted for demographics, smoking history, FEV1 % predicted after bronchodilator administration, and number of visits that the participant completed, we assessed the association of BDR group: (1) consistent BDR, (2) inconsistent BDR, and (3) never BDR with asthma, CT scan features, blood eosinophil levels, and FEV1 decline in participants without COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stage 0) and the entire cohort (participants with or without COPD). RESULTS: Both consistent and inconsistent ATS-BDR were associated with asthma history and greater small airways disease (%parametric response mapping functional small airways disease) relative to never ATS-BDR in participants with GOLD stage 0 disease and the entire cohort. We observed similar findings using FEV1-BDR and FVC-BDR definitions. Eosinophils did not vary consistently among BDR groups. Consistent BDR was associated with FEV1 decline over time relative to never BDR in the entire cohort. In participants with GOLD stage 0 disease, both the inconsistent ATS-BDR group (OR, 3.20; 95% CI, 2.21-4.66; P < .001) and consistent ATS-BDR group (OR, 9.48; 95% CI, 3.77-29.12; P < .001) were associated with progression to COPD relative to the never ATS-BDR group. INTERPRETATION: Demonstration of BDR, even once, describes an obstructive lung disease phenotype with a history of asthma and greater small airways disease. Consistent demonstration of BDR indicated a high risk of lung function decline over time in the entire cohort and was associated with higher risk of progression to COPD in patients with GOLD stage 0 disease.
引用
- Fortis S, Quibrera PM, Comellas AP, et al. Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD. Chest. 2022. PMID: 36395858. doi:10.1016/j.chest.2022.11.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。